Clinical Trials in Xi'an, Shannxi
20 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc.600 enrolled42 locationsNCT07217301
Recruiting
Phase 1Phase 2
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Esophageal Squamous Cell CarcinomaNeoadjuvantIvonescimab
Tang-Du Hospital45 enrolled1 locationNCT07385001
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 2
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
SCLC,Extensive Stage
Tang-Du Hospital32 enrolled1 locationNCT07141264
Recruiting
Not Applicable
Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
Alzheimer DiseaseTranscranial Magnetic StimulationCerebellum
Xijing Hospital100 enrolled4 locationsNCT06669182
Recruiting
Phase 2
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Breast Cancer
Xijing Hospital27 enrolled2 locationsNCT06914440
Recruiting
Phase 2
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.134 enrolled28 locationsNCT06897579
Recruiting
Not Applicable
LAAO Versus NOAC in Patients with AF and PCI
Atrial FibrillationPercutaneous Coronary Intervention
Xijing Hospital1,386 enrolled1 locationNCT05353140
Recruiting
Phase 2
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Esophageal Cancer
Tang-Du Hospital80 enrolled1 locationNCT06663059
Recruiting
Phase 2
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Small Cell Lung Cancer ( SCLC )
Tang-Du Hospital104 enrolled1 locationNCT06485544
Recruiting
Phase 2
Adebrelimab + Apatinib in SCLC Maintenance Therapy
SCLC
Tang-Du Hospital60 enrolled1 locationNCT06475209
Recruiting
Phase 4
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Small Cell Lung Cancer
Tang-Du Hospital24 enrolled1 locationNCT06467786
Recruiting
Phase 2
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
Gastric Cancer
Tang-Du Hospital42 enrolled1 locationNCT06475417
Recruiting
Phase 4
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Pancreatic Cancer Resectable
Xi'an Jiaotong University642 enrolled1 locationNCT06368063
Recruiting
Phase 1
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.150 enrolled20 locationsNCT06115902
Recruiting
Phase 1Phase 2
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Xijing Hospital30 enrolled1 locationNCT06082934
Recruiting
Not Applicable
Low-dose NOAC Versus GDMT After LAAO
Atrial Fibrillation
Xijing Hospital4,220 enrolled1 locationNCT05960721
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Esophageal Cancer
Fudan University385 enrolled11 locationsNCT05443841